^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

GW8510

i
Other names: GW8510, GW 8510, GW-8510
Associations
Trials
Company:
Ege University, GSK
Drug class:
CDK2 inhibitor
Associations
Trials
2years
Construction of the prognostic enhancer RNA regulatory network in osteosarcoma. (PubMed, Transl Oncol)
We constructed an eRNA-based prognostic model for predicting the OS patients' prognosis and explored the potential regulation network for OS tumorigenesis by an integrated bioinformatics analysis, providing promising therapeutic targets for OS patients.
Journal
|
CD8 (cluster of differentiation 8) • CEBPA (CCAAT Enhancer Binding Protein Alpha)
|
GW8510
over2years
Cyclin-Dependent Kinase Inhibitors Function as Potential Immune Regulators via Inducing Pyroptosis in Triple Negative Breast Cancer. (PubMed, Front Oncol)
More importantly, in vitro and in vivo studies confirmed that GW-8510 and other CDK inhibitors (Dinaciclib, and Palbociclib) can induce pyroptosis by activating caspase-3 and GSDME, which might be the mechanism for their immune regulation potentials. GW-8510, as well as other CDK inhibitors, might serve as potential immune regulators and pyroptosis promotors in TNBC.
Journal • IO biomarker
|
CASP3 (Caspase 3) • GSDME (Gasdermin E)
|
Ibrance (palbociclib) • dinaciclib (MK-7965) • GW8510
3years
Expression and clinical significance of TIMELESS in glioma. (PubMed, Int J Clin Exp Pathol)
We predict small molecules to inhibit TIMELESS such as 8-azaguanine, gw8510, 6-thioguanosine, and ursodeoxycholic acid. This study is the first comprehensive analysis of TIMELESS, revealing a relationship between this novel oncogene, clinical characteristics of patients with glioma, and a mechanism leading to poor prognosis. It also provides a biomarker for diagnosis and treatment of glioma and reveal the pathologic progress of glioma at the genetic level.
Clinical • Journal
|
TIMELESS (Timeless Circadian Regulator)
|
GW8510